• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:05:17 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    8-K
    false000176230300017623032025-05-082025-05-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 08, 2025

     

     

    AVITA Medical, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39059

    85-1021707

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    28159 Avenue Stanford

    Suite 220

     

    Valencia, California

     

    91355

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 661 367-9170

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    RCEL

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On May 8, 2025, the Company issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description of Exhibit

    99.1

     

    Press release, dated May 8, 2025, issued by AVITA Medical, Inc.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    AVITA Medical, Inc.

     

     

     

     

    Date:

    May 8, 2025

    By:

    /s/ David O'Toole

     

     

     

    David O'Toole
    Chief Financial Officer

     

     


    Get the next $RCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Financials

    Live finance-specific insights

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business Updates Commercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023Gross profit margin of 87.6%On December 19, 2024, the FDA granted 510(k) clearance for Cohealyx™, an AVITA Medical-branded collagen-based dermal matrixOn December 23, 2024, the FDA approved RECELL GO® miniOn February 13, 2025, amended the credit

      2/13/25 4:01:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avita Medical Inc.

      10-Q - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:15:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:05:17 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Avita Medical Inc.

      DEF 14A - AVITA Medical, Inc. (0001762303) (Filer)

      4/22/25 4:30:18 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    See more

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer

      VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public

      6/15/23 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Appoints New Non-Executive Member to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023. Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He

      3/23/23 4:30:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

      VALENCIA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will host its inaugural Acute Wound Care Showcase 2025 on Tuesday, May 13, 2025, via webcast at 11:00 a.m. Pacific Time. The event will feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs. The Acute Wound Care Showcase will provide an overview of AVITA Medical's comprehensive approach to acute wound care. Attendees joining the webcast will gain insights into the company's product portfolio, includi

      4/24/25 9:00:00 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Avita Medical with a new price target

      D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00

      12/24/24 7:10:27 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical downgraded by BTIG Research

      BTIG Research downgraded Avita Medical from Buy to Neutral

      4/11/24 7:58:22 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Avita Medical with a new price target

      Cantor Fitzgerald initiated coverage of Avita Medical with a rating of Overweight and set a new price target of $23.00

      6/27/23 7:26:40 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      2/13/24 4:58:57 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      1/26/24 4:23:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

      SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

      2/9/23 11:07:47 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care